Sort
10,766 grants matching “checkpoint inhibitor”
Development of Novel Informative Preclinical Animal Models - CAPR Infrastructure
$230,821Shyam Sharan · Division Of Basic Sciences - Nci · ZIG · FY2022 · CA
Developing Novel NLRX1-Based Immuno-Oncology Therapeutics
$230,729Andrew Leber · Biotherapeutics, Inc. · R43 · FY2020 · CA
Targeting Tumor-Driven Immune Tolerance to Overcome Resistance to Hedgehog Inhibition
$230,711Arianna L Kim · Columbia University Health Sciences · R21 · FY2025 · CA
Project 1: Targeting Metastatic Prostate Cancer Patients with Biallelic Loss of CDK12
$230,649Arul M Chinnaiyan · University Of Michigan At Ann Arbor · P50 · FY2023 · CA
Evaluation of T follicular regulatory cells as novel cellular targets of cancer immunotherapy
$230,407Simon Eschweiler · University Of Tx Md Anderson Can Ctr · R37 · FY2024 · CA
Dual function of HSP70 in cytoprotection of tumor cells and generation of permissive microenvironment
$230,387Hasan Korkaya · Wayne State University · R01 · FY2023 · CA
Mitotic Mechanisms in Alzheimer's Disease
$230,171Blair Leavitt · University Of British Columbia · R01 · FY2006 · AG
Effect of oncolytic herpesvirus on the tumor microenvironment
$230,079Paul Rider · Lsu Health Sciences Center · P20 · FY2019 · GM
Reversible vitamin A-dependent arrest of spermatogonia
$229,950University Of North Carolina Chapel Hill · R01 · FY2004 · HD
Reversible vitamin A-dependent arrest of spermatogonia
$229,950University Of North Carolina Chapel Hill · R01 · FY2003 · HD
Reversible vitamin A-dependent arrest of spermatogonia
$229,950University Of North Carolina Chapel Hill · R01 · FY2005 · HD
Flow Cytometry Core
$229,860W Martin Kast · University Of Southern California · P30 · FY2023 · CA
B55 alpha deficiency as a therapeutic target in cancer
$229,685Junran Zhang · Ohio State University · R01 · FY2023 · CA
Germline genetic factors regulating immune response to tumors and their contribution to colorectal cancer risk and prognosis
$229,680Jeroen R Huyghe · Fred Hutchinson Cancer Research Center · R21 · FY2019 · CA
A20 Promotes Glioma Stem Cell Mediated Tumorigenesis
$229,598Anita Borton Hjelmeland · University Of Alabama At Birmingham · R01 · FY2014 · CA
Preclinical assessment of efficacy and tumor microenvironment alterations by PPRX-1701 in glioblastoma
$229,519Sean Edward Lawler · Brown University · R21 · FY2023 · CA
Nitrosourea-induced growth arrest and apoptotic pathways
$229,293University Of Florida · R01 · FY2004 · CA
Nitrosourea-induced growth arrest and apoptotic pathways
$229,163University Of Florida · R01 · FY2005 · CA
Rare Central Nervous System Cancers Initiative
$229,124Mark Gilbert · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Project 1: 5FU and Vitamin D as Neoadjuvants for Photodynamic Priming to Enhance Skin Cancer Therapy
$229,036Edward V. Maytin · Massachusetts General Hospital · P01 · FY2022 · CA
Project 2: Intratumoral PDT Induces PDP-based Enhancement of PD-1 Inhibition in Pancreatic Carcinoma
$228,869Kenneth K Wang · Massachusetts General Hospital · P01 · FY2022 · CA
CD73 expression on cancer-associated fibroblasts of Head and Neck Cancers shapes the immune landscape
$228,750Yan Cui · Augusta University · R21 · FY2019 · DE
Early Clinical Trials of New Anti-Cancer Agents with Phase 1 Emphasis
$228,694David R Spriggs · Sloan-Kettering Inst Can Research · U01 · FY2013 · CA
Ras18-mediated Fanconi Anemia pathway activation in response to camptothecin
$228,690Komaraiah Palle · University Of South Alabama · R01 · FY2016 · GM
Ras18-mediated Fanconi Anemia pathway activation in response to camptothecin
$228,690Komaraiah Palle · University Of South Alabama · R01 · FY2015 · GM